Lastly, we postulate how variable melanocyte fates in vitiligo, albinism, psoriasis, and alopecia areata may provide ... intercellular communication (melanocyte-keratinocyte-fibroblast), as well as ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic ...

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis. “Its mechanism of action is fairly unique in dermatology,” Bissonnette ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...